Every finding on record at Suncrest Hospice Phoenix, LLC

It is required that the documented comprehensive assessment includes a drug profile that contains the patient's current: prescription and over-the-counter (OTC) drugs, Supplements, Herbal remedies, Other alternative treatments that could affect drug therapy. The medication review process includes the identification of the following: the effectiveness of drug therapy, drug side effects, actual or potential drug interactions, duplicate drug therapy, and drug therapy associated with laboratory monitoring. The assessment includes evidence that common side effects of medication in the hospice populations are anticipated, and, as appropriate, preventive measurements are implemented to manage the side effects. The drug profile is updated per the hospice policy and procedure, but, at minimum, at the time of each comprehensive assessment and/or when a new medication is added or changes are made to existing medication. This standard was not met as evidenced by a review of clinical records and interviews. 1 of 3 (33%) clinical records reviewed, the drug profile did not reflect all medications the patient was taking. Clinical Record 9: Hospice clinical record plan of care dated 9/13/2022 listed Miconazole topical powder; take 1 application applied topically 2 times per day; 1 application topically to bilateral breasts bid until rash resolved: Date 7/11/2022. Calmoseptine 0.44%-20.6% topical ointment: Apply 1 milliliter(s) topical 3 times per day as needed for redness, with brief changes. Date: 9/19/2021. Calmoseptine and Miconazole were not listed as provided on the facility physician orders, routine medications, prn medications or treatment orders. Medication profile policy No.2-004 states the medication profiles will be updated for each change to reflect current medications and new and/or discontinued medications. After further review, the Regional Administrator confirmed the medication profile did not match the facility profile. See below